QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)
NASDAQ:ENGN

enGene (ENGN) Stock Price, News & Analysis

$15.89
+0.58 (+3.79%)
(As of 04:27 PM ET)
Today's Range
$15.01
$16.23
50-Day Range
$6.92
$16.50
52-Week Range
$6.69
$43.00
Volume
66,290 shs
Average Volume
45,562 shs
Market Capitalization
$368.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

enGene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
95.1% Upside
$31.00 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.03mentions of enGene in the last 14 days
Based on 43 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.52 out of 5 stars

Medical Sector

284th out of 945 stocks

Holding & Other Investment Offices Industry

1st out of 12 stocks


ENGN stock logo

About enGene Stock (NASDAQ:ENGN)

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

ENGN Stock Price History

ENGN Stock News Headlines

INDUSTRY: Atom Engine
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
See More Headlines
Receive ENGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Holding & other investment offices
Sub-Industry
N/A
Current Symbol
NASDAQ:ENGN
Previous Symbol
NASDAQ:ENGN
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$31.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+102.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$355.19 million
Optionable
N/A
Beta
-1.07
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Jason D. Hanson Esq. (Age 55)
    J.D., CEO & Director
    Comp: $656.58k
  • Dr. Alex Nichols Ph.D. (Age 38)
    President & COO
    Comp: $504.44k
  • Dr. James C. Sullivan M.Sc. (Age 45)
    Ph.D., Chief Scientific Officer
    Comp: $524.29k
  • Dr. Anthony T. Cheung Ph.D. (Age 52)
    Co-Founder & CTO
    Comp: $341.75k
  • Mr. John C. Brown D.Sc.
    FRSC, Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Mr. David Ryan Daws (Age 50)
    CFO & Head of Business Development
  • Mr. Lee G. Giguere (Age 43)
    Chief Legal Officer & Corporate Secretary
  • Ms. Sharon Tan
    VP of Project Management & Head of Program Management
  • Dr. Richard P. Bryce MBChB (Age 67)
    MFPM, MRCGP, Chief Medical Officer
  • Mr. Paul Erickson
    Non-Executive Director














ENGN Stock Analysis - Frequently Asked Questions

Should I buy or sell enGene stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for enGene in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENGN shares.
View ENGN analyst ratings
or view top-rated stocks.

What is enGene's stock price target for 2024?

2 analysts have issued 1 year target prices for enGene's shares. Their ENGN share price targets range from $31.00 to $31.00. On average, they expect the company's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 95.1% from the stock's current price.
View analysts price targets for ENGN
or view top-rated stocks among Wall Street analysts.

How have ENGN shares performed in 2024?

enGene's stock was trading at $9.23 at the beginning of the year. Since then, ENGN shares have increased by 72.2% and is now trading at $15.89.
View the best growth stocks for 2024 here
.

Who are enGene's major shareholders?

enGene's stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.70%), Blue Owl Capital Holdings LP (5.32%), Omega Fund Management LLC (4.88%), Vivo Capital LLC (2.93%), Royal Bank of Canada (0.16%) and Goldman Sachs Group Inc. (0.16%).

How do I buy shares of enGene?

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENGN) was last updated on 2/28/2024 by MarketBeat.com Staff